Effect of a PAF antagonist, BN52063, on antigen-induced, acute, and late-onset cutaneous responses in atopic subjects.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Journal of Allergy and Clinical Immunology

• Publication date

  1988-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0091-6749(88)91005-6PMID 3403863
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man.

  1987cited by this paper
• Triazolodiazepines: dissociation of their Paf (platelet activating factor) antagonistic and CNS activity

  1987cited by this paper
• Inhibition of PAF-acether induced weal and flare reaction in man by a specific PAF antagonist.

  1986cited by this paper
• Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils.

  1986cited by this paper
• Accumulation of eosinophils in response to intracutaneous PAF-acether and allergens in man.

  1986cited by this paper
• Histamine is released from skin by substance P but does not act as the final vasodilator in the axon reflex

  1986cited by this paper
• Properties of PAF-acether Appropriate to a Mediator of Inflammation

  1985cited by this paper
• Accumulation of inflammatory cells in response to intracutaneous platelet activating factor (Paf‐acether) in mang

  1985cited by this paper
• BN 52021 and related compounds: A new series of highly specific PAF-acether receptor antagonists isolated from Ginkgo biloba L.

  1985cited by this paper
• Inflammatory characteristics of platelet activating factor (PAF‐acether) in human skin

  1984cited by this paper
• The platelet in asthma.

  1984cited by this paper
• Induction of late cutaneous reaction by kallikrein injection: comparison with allergic-like late response to compound 48/80.

  1983cited by this paper
• CV-3988 - a specific antagonist of platelet activating factor (PAF).

  1983cited by this paper
• Antigen-induced local mediator release and cellular inflammatory responses in atopic subjects.

  1983cited by this paper
• A comparison of the in vivo effects of ketotifen, clemastine, chlorpheniramine and sodium cromoglycate on histamine and allergen induced weals in human skin.

  1983cited by this paper
• Inhibition of neurogenic vasodilation and plasma extravasation by substance P antagonists, somatostatin and [D-Met2, Pro5]enkephalinamide.

  1982cited by this paper
• INTERACTION OF NEUROTENSIN WITH THE SUBSTANCE P RECEPTOR MEDIATING HISTAMINE RELEASE FROM RAT MAST CELLS AND THE FLARE IN HUMAN SKIN

  1982cited by this paper
• Mediator studies in skin blister fluid from patients with dual skin reactions after intradermal allergen injection.

  1982cited by this paper
• Effect of Topical Indomethacin on Allergen‐Induced Dual Skin Reactions

  1980cited by this paper
• An evaluation of the pharmacologic inhibition of the immediate and late cutaneous reaction to allergen

  1980cited by this paper
• Production of IgE complexes by allergen challenge in atopic patients and the effect of sodium cromoglycate.

  1979cited by this paper
• Dual skin test reactions and serum antibodies to subtilisin and Aspergillus fumigatus extracts

  1978cited by this paper
• Relative refractory state for late cutaneous allergic responses.

  1977cited by this paper
• The late phase of the immediate wheal and flare skin reaction. Its dependence upon IgE antibodies.

  1976cited by this paper
• Factors which influence late cutaneous allergic responses.

  1976cited by this paper
• Late cutaneous allergic responses in isolated IgE-dependent reactions.

  1973cited by this paper
• Cutaneous reactions to kallikrein, bradykinin and histamine in healthy subjects and in patients with urticaria.

  1969cited by this paper

• Znaczenie osoczowej acetylohydrolazy PAF w chorobach alergicznych – aktualny stan wiedzy

  2016cites this paper
• Effect of Premedications in a Murine Model of Asparaginase Hypersensitivity

  2015cites this paper
• Potential Therapeutic Strategies for Severe Anaphylaxis Targeting Platelet-Activating Factor and PAF Acetylhydrolase

  2014cites this paper
• Pharmacology of airway inflammation in asthma

  2007cites this paper
• Comparison of weal and flare responses to platelet activating factor (PAF) and histamine, and the ultrastructural effects of PAF in the skin of atopic and normal subjects

  1999cites this paper
• Topical application of a platelet-activating factor (PAF) antagonist in atopic dermatitis.

  1997cites this paper
• Effect of platelet activating factor (PAF) on the migration of human lymphocytes.

  1995cites this paper
• Platelet activating factor mimics antigen-induced cutaneous inflammatory responses in sweet itch horses.

  1995cites this paper
• Actions of PAF receptor antagonists in horses with the allergic skin disease sweet itch

  1995cites this paper
• Clinical experience with platelet-activating factor antagonists

  1995cites this paper
• Do Platelets have a Role as Inflammatory Cells

  1995cites this paper
• Structural and (Patho)physiological diversity of PAF

  1995cites this paper
• Clinical experience with platelet-activating factor antagonists. Past, present, and near future.

  1994cites this paper
• Inhibitory effect of UK,74505, a potent and specific oral platelet activating factor (PAF) receptor antagonist, on airway and systemic responses to inhaled PAF in humans.

  1994cites this paper
• Pulmonary iimmune ccells iin hhealth aand ddisease: pplatelets

  1994cites this paper
• Advances in anti-inflammatory therapy.

  1994cites this paper
• Pulmonary immune cells in health and disease: platelets.

  1994cites this paper
• Effect of BN 50730, a Specific PAF Antagonist, on PAF-Induced Platelet Aggregation and Skin Responses in Healthy Human Volunteers

  1994cites this paper
• [Effects of PAF antagonists in experimental models. Therapeutical perspectives].

  1993cites this paper
• Effect of the platelet-activating factor antagonist UK-74,505 on the early and late response to allergen.

  1993cites this paper
• Platelet activating factor—a mediator of inflammation in the skin—medical implications

  1993cites this paper
• The platelet in asthma.

  1993cites this paper
• Cytokines, platelet activating factor and eosinophils in asthma.

  1992cites this paper
• Mechanisms of hyperresponsiveness: platelet-activating factor.

  1992cites this paper
• Inflammatory mechanisms in the passive cutaneous anaphylactic reaction in the rabbit: evidence that novel mediators are involved

  1992cites this paper
• Role of inflammatory mediators in asthma.

  1992cites this paper
• The Pathophysiological Role and Therapeutic Implications of Platelet Activating Factor in Diseases of Aging

  1992cites this paper
• Inflammatory effects of platelet activating factor (PAF) in equine skin.

  1992cites this paper
• Overview: PAF Receptor Antagonists: Recent Advances

  1992cites this paper
• Phospholipids and their inhibitors: A critical evaluation of their role in the treatment of sepsis

  1992cites this paper
• Triazolam and PAF.

  1991cites this paper
• The contribution of platelet-activating factor to allergen-induced eosinophil infiltration and bronchial hyperresponsiveness

  1991cites this paper
• Triazolam and PAF

  1991cites this paper
• Role for platelet-activating factor in asthma

  1991cites this paper
• Histamine releasing factors and cytokine-dependent activation of basophils and mast cells.

  1991cites this paper
• Platelet-activating factor-induced immediate and late cutaneous reactions.

  1991cites this paper
• Effect of long-term infusion of platelet-activating factor on pulmonary responsiveness and morphology in the guinea-pig.

  1991cites this paper
• Effects of PAF antagonist, BN52021, on the PAF-, methacholine-, and allergen-induced bronchoconstriction in asthmatic children.

  1991cites this paper
• Platelet Activating Factor and Asthma

  1991cites this paper
• Measurement of platelet-activating factor in biological specimens.

  1991cites this paper
• The release of platelet-activating factor into plasma during allergen-induced bronchoconstriction.

  1991cites this paper
• Drug Therapy of Chronic Urticaria and Angioedema

  1991cites this paper
• PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

  1991cites this paper
• [Detection of platelet-activating factor in nasal lavage fluid from patients with pollinosis and experimental animals with nasal allergy].

  1990cites this paper
• Lipid mediators in inflammatory skin disorders.

  1990cites this paper
• Venous blood platelets decrease during allergen‐induced asthmatic reactions

  1990cites this paper
• Preclinical and clinical pharmacology of platelet‐activating factor receptor antagonists

  1990cites this paper
• Pro-Inflammatory Mediators and Human Skin Disease

  1990cites this paper
• Effects of a PAF-antagonist (BN 52063) on bronchoconstriction and platelet activation during exercise induced asthma.

  1990cites this paper
• The role of platelet activating factor in allergic respiratory disease.

  1990cites this paper
• Preventive effect of several drugs againstPseudomonas aeruginosa infection and the toxicity of combined tumor necrosis factor with lipopolysaccharide: Relationship between lethality and the arachidonic cascade

  1990cites this paper
• Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.

  1990cites this paper
• Allergic Inflammatory Mediators and Bronchial Hyperresponsiveness

  1990cites this paper
• Generation of oxygen free radicals from blood eosinophils from asthma patients after stimulation with PAF or phorbol ester.

  1990cites this paper
• In vivo effects of cetirizine on cutaneous reactivity and eosinophil migration induced by platelet-activating factor (PAF-acether) in man.

  1990cites this paper
• Chapter 9. PAF Antagonists

  1989cites this paper
• Modification of allergen-induced airway obstruction and airway hyperresponsiveness in an allergic rabbit model by the selective platelet-activating factor antagonist, BN 52021.

  1989cites this paper
• Our changing understanding of asthma.

  1989cites this paper
• The role of platelet activating factor in allergic inflammation.

  1989cites this paper
• From anti-asthma drugs to PAF-acether antagonism and back. Present status.

  1989cites this paper
• Effect of topical capsaicin on the cutaneous responses to inflammatory mediators and to antigen in man.

  1989cites this paper
• Effect of long-term administration of platelet-activating factor on pulmonary responsiveness and morphology in the guinea pig.

  1989cites this paper
• New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma.

  1989cites this paper
• The role of platelet-activating factor in asthma.

  1988cites this paper
• PAF antagonists. Their potential therapeutic role in asthma.

  1988cites this paper
• The drug therapy of asthma: directions for the 21st century.

  1988cites this paper
• Effect of a PAF antagonist, BN52063, on PAF-induced bronchoconstriction in normal subjects.

  1988cites this paper
• PAF Antagonists

  1988cites this paper